SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-437371"
 

Search: onr:"swepub:oai:DiVA.org:uu-437371" > Consensus on molecu...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005623naa a2200721 4500
001oai:DiVA.org:uu-437371
003SwePub
008210309s2021 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4373712 URI
0247 a https://doi.org/10.1016/j.ejca.2021.01.0082 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a for2 swepub-publicationtype
1001 a Ambrosini, Valentina4 aut
2451 0a Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
264 1b Elsevier,c 2021
338 a print2 rdacarrier
520 a Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). European Association of Nuclear Medicine (EANM) Focus 3 performed a multidisciplinary Delphi process to deliver a balanced perspective on molecular imaging and radionuclide therapy in well-differentiated neuroendocrine tumours (NETs). NETs form in cells that interact with the nervous system or in glands that produce hormones. These cells, called neuroendocrine cells, can be found throughout the body, but NETs are most often found in the abdomen, especially in the gastrointestinal tract. These tumours may also be found in the lungs, pancreas and adrenal glands. In addition to being rare, NETs are also complex and may be difficult to diagnose. Most NETs are non-functioning; however, a minority present with symptoms related to hypersecretion of bioactive compounds. NETs often do not cause symptoms early in the disease process. When diagnosed, substantial number of patients are already found to have metastatic disease. Several societies' guidelines address Neuroendocrine neoplasms (NENs) management; however, many issues are still debated, due to both the difficulty in acquiring strong clinical evidence in a rare and heterogeneous disease and the different availability of diagnostic and therapeutic options across countries. EANM Focus 3 reached consensus on employing 68gallium-labelled somatostatin analogue ([68Ga]Ga-DOTA-SSA)-based PET/CT with diagnostic CT or magnetic resonance imaging (MRI) for unknown primary NET detection, metastatic NET, NET staging/restaging, suspected extra-adrenal pheochromocytoma/paraganglioma and suspected paraganglioma. Consensus was reached on employing 18fluorine-fluoro-2-deoxyglucose ([18F]FDG) PET/CT in neuroendocrine carcinoma, G3 NET and in G1-2 NET with mismatched lesions (CT-positive/[68Ga]Ga-DOTA-SSA-negative). Peptide receptor radionuclide therapy (PRRT) was recommended for second line treatment for gastrointestinal NET with [68Ga]Ga-DOTA-SSA uptake in all lesions, in G1/G2 NET at disease progression, and in a subset of G3 NET provided all lesions are positive at [18F]FDG and [68Ga]Ga-DOTA-SSA. PRRT rechallenge may be used for in patients with stable disease for at least 1 year after therapy completion. An international consensus is not only a prelude to a more standardised management across countries but also serves as a guide for the direction to follow when designing new research studies.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Consensus
653 a Molecular imaging
653 a Neuroendocrine neoplasms
653 a PRRT
7001 a Kunikowska, Jolanta4 aut
7001 a Baudin, Eric4 aut
7001 a Bodei, Lisa4 aut
7001 a Bouvier, Catherine4 aut
7001 a Capdevila, Jaume4 aut
7001 a Cremonesi, Marta4 aut
7001 a de Herder, Wouter W4 aut
7001 a Dromain, Clarisse4 aut
7001 a Falconi, Massimo4 aut
7001 a Fani, Melpomeni4 aut
7001 a Fanti, Stefano4 aut
7001 a Hicks, Rodney J4 aut
7001 a Kabasakal, Levent4 aut
7001 a Kaltsas, Gregory4 aut
7001 a Lewington, Val4 aut
7001 a Minozzi, Silvia4 aut
7001 a Cinquini, Michela4 aut
7001 a Öberg, Kjell,d 1946-u Uppsala universitet,Endokrin tumörbiologi4 aut0 (Swepub:uu)kjellob
7001 a Oyen, Wim J G4 aut
7001 a O'Toole, Dermot4 aut
7001 a Pavel, Marianne4 aut
7001 a Ruszniewski, Philippe4 aut
7001 a Scarpa, Aldo4 aut
7001 a Strosberg, Jonathan4 aut
7001 a Sundin, Anders,d 1954-u Uppsala universitet,Radiologi4 aut0 (Swepub:uu)anderssu
7001 a Taïeb, David4 aut
7001 a Virgolini, Irene4 aut
7001 a Wild, Damian4 aut
7001 a Herrmann, Ken4 aut
7001 a Yao, James4 aut
7102 a Uppsala universitetb Endokrin tumörbiologi4 org
7730 t European Journal of Cancerd : Elsevierg 146, s. 56-73q 146<56-73x 0959-8049x 1879-0852
8564 u http://manuscript.elsevier.com/S0959804921000198/pdf/S0959804921000198.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-437371
8564 8u https://doi.org/10.1016/j.ejca.2021.01.008

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view